<DOC>
	<DOCNO>NCT01958008</DOCNO>
	<brief_summary>The main objective current trial investigate safety , tolerability pharmacokinetics BI 113608 COPD patient symptoms chronic bronchitis .</brief_summary>
	<brief_title>BI 113608 Administered Tablets Twice Daily Over 4 Weeks Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent ICHGCP guideline local legislation prior studyrelated procedure , include medication washout restriction . 2 . All patient must document diagnosis COPD accord GOLD 2013 . 3 . Postbronchodilator 50 % = FEV1 &lt; 80 % predict screening visit . 4 . Postbronchodilator FEV1/FVC &lt; 70 % screen visit . 5 . Patients must history chronic bronchitis define symptom cough sputum production day least three month past two consecutive year . 6 . CAT Questionnaire screening : score least one cough ( 1st question ) sputum ( 2nd question ) . 7 . Males females 40 80 year ( inclusive ) age , day patient´s signature inform consent . 8 . Patients must current exsmokers smoke history 10 pack year . Patients never smoke cigarette must exclude . 9 . Patients must able perform technically acceptable pulmonary function test ( body plethysmography , force spirometry DLCO measurement ) . 10 . Females must nonchildbearing potential . Women nonchildbearing potential define undergone bilateral ovariectomy , bilateral salpingectomy hysterectomy . If , documentation confirm surgical procedure must available patient 's source document . A woman also presume infertile due natural cause amenorrheic 24 month . In questionable case , blood analysis FSH estradiol , indicate postmenopausal status accord central laboratory range postmenopausal female , consider confirmatory . Exclusion criterion : 1 . Significant pulmonary disease COPD medical conditions* ( determined medical history , examination , clinical investigation screen ) may , opinion investigator , result following : 1 . Put patient risk participation study , 2 . Influence result study , 3 . Cause concern regard patient 's ability participate study . ( *e.g . cardiac , gastrointestinal , hepatic , renal , metabolic , dermatologic , neurological , haematological , oncological psychiatric ; history relevant orthostatic hypotension , faint spell blackout ; current chronic relevant acute infection . ) 2 . Patients lung disease COPD ( e.g . asthma , interstitial lung disease ( ILD ) , cystic fibrosis , active tuberculosis , postTB syndrome , clinically evident bronchiectasis , history thoracotomy pulmonary resection ) . 3 . Patients clinically relevant abnormal haematology , blood chemistry , urinalysis screen visit ( Visit 1 ) , abnormality defines relevant disease define exclusion criterion number 1 . 4 . All patient serum glutamate oxaloacetate transferase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) total bilirubin high 1.5fold ULN serum creatinine high normal Visit 1 ( repeat test , applicable ) exclude regardless clinical condition . Laboratory evaluation repeat maximum two time . 5 . A malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) . 6 . Patients current relevant psychiatric disorder base investigator´s judgement . 7 . Patients respiratory infection ( e.g . common cold , sinusitis , etc . ) COPD exacerbation within six week prior screen visit ( Visit 1 ) screen visit randomization . 8 . Patients history two moderate severe COPD exacerbation per year within last two year . 9 . Patients history and/or active significant alcohol drug abuse . See exclusion criterion number 1 . 10 . Patients treat nonpermitted concomitant medication . 11 . Patients recent history ( i.e . three year less ) heart failure patient cardiac arrhythmia require drug therapy . 12 . Patients previously randomise trial . 13 . Current participation another clinical trial ( define ICH Harmonised Tripartite Guideline Good Clinical Practice ( GCP ) ) . 14 . Donation 100 mL blood within past four week prior screen . 15 . A history additional risk factor torsadedepointes ( e.g. , heart failure , relevant hypokalemia , family history Long QT Syndrome ) . 16 . Pregnant nursing woman . 17 . Gastrointestinal tract surgery might affect absorption elimination drug . 18 . Patients know hypersensitivity / allergy investigational medicinal product ( IMP ) excipients . 19 . Male Patients agree minimize risk female partner become pregnant first dose day two month study completion .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>